← All trials
NCT05450887
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 23, 2021
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2024
- First posted
- Jul 11, 2022
- Last posted
- Jul 11, 2022
- Enrollment
- 156
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.